Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007342
Chunk: 30

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 30
---
.05
million, before deducting agent fees and expenses. Additionally, we issued warrants to purchase 6,456 of our Depositary Shares in connection
with the offering to the warrant agent and certain of their designees, or Warrant Agent Warrants.

Between December 21, 2023
and April 1, 2025, we have issued 2,477,566,800 Ordinary Shares upon the exercise of the pre-funded warrants, Series E Warrants and Series
F Warrants issued in the December 2023 underwritten public offering and private placement, including warrants exercised pursuant to the
terms of the letter agreements entered into with certain accredited investors on May 22, 2024, or the Warrant Agreements (other than shares
held in abeyance).

On July 22, 2024, we sold in a registered direct offering an aggregate of (i) 202,032 Depositary Shares and (ii) 11,157 pre-funded warrants, or July 2024 Pre-Funded Warrants, at a price per Depositary Share of $23.50, and a price per July 2024 Pre-Funded Warrant of $23.4975, and in a concurrent private placement, we issued and sold (x) Series J warrants, or Series J Warrants, exercisable for 213,188 Depositary Shares, and (y) Series K warrants, or Series K Warrants, to purchase an aggregate of 213,188 Depositary Shares. The warrants are immediately exercisable at an exercise price of $25.00 per Depositary Share, subject to adjustments for certain dilutive equity issuances. The aggregate gross proceeds to the Company were approximately $5.0 million. Additionally, we issued warrants to purchase 8,525 of our Depositary Shares in connection with the offering to the placement agent and certain of its designees, or the July 2024 Placement Agent Warrants.

On October 4, 2024, we effected
a ratio change to the Depositary Shares, pursuant to which the ratio of Ordinary Shares to Depositary Shares was changed such that one
Depositary Share represented 10,000 Ordinary Shares. Our Ordinary Shares were not affected by this change and no fractional Depositary
Shares were issued.

On November 22, 2024, we held
the November GM and our shareholders passed resolutions to, among other things, subdivide our Ordinary Shares of £0.001 nominal
value each into one Ordinary Share of